{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-24-000091","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.372325+00:00","generated_at":"2026-06-02T04:52:13.390558+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MacroGenics Q1 net loss $52.2M; interim TAMARACK data shows vobra duo activity in mCRPC","bullets":["Q1 net loss $52.2M ($0.84/share) vs $38.0M loss in Q1 2023; total revenue $9.1M, down from $24.5M.","Cash, equivalents and marketable securities $184.2M as of March 31, 2024; cash runway expected into 2026.","Interim TAMARACK data: vobra duo 2.0 mg/kg q4W showed confirmed PSA≥50% reduction in 36/82 (43.9%) and ORR of 17.8%.","Five fatal AEs reported in TAMARACK; two pneumonitis deaths in 2.7 mg/kg cohort; Phase 3 planning initiated for 2025.","Company plans to expand TAMARACK to NSCLC, SCLC, melanoma and other indications in mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-24-000091","json":"https://secwatch.observer/filing/0001125345-24-000091.json","markdown":"https://secwatch.observer/filing/0001125345-24-000091.md","text":"https://secwatch.observer/filing/0001125345-24-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/0001125345-24-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/mgnx-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:52:13.390558+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d90b3971ea6247578bf212116876f461277ecf55","claim":"MACROGENICS INC reported financial results for quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, MacroGenics, Inc. (the \"Company\") announced financial and operating results as of and for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1125345/000112534524000091/0001125345-24-000091-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}